ASPETTI ETICI ED OPERATIVI OGGETTO DI AUDIT IN UNA SPERIMENTAZIONE IN PAESI IN VIA DI SVILUPPO
|
|
- Michael Pearson
- 6 years ago
- Views:
Transcription
1 ASPETTI ETICI ED OPERATIVI OGGETTO DI AUDIT IN UNA SPERIMENTAZIONE IN PAESI IN VIA DI SVILUPPO N.B. Per motivi di riservatezza alcune informazioni sulla sperimentazione non sono riportate Umberto Filibeck UNICRI Progetto Promozione GGPnei PVS Docente Master in sperimentazioni cliniche 1 Università Tor Vergata Roma EU requirements for clinical trials conducted in third countries Directive 2001/83/EC as amended by Directive 2004/27 - Whereas.(13) : ethical requirements of Directive 2001/20/EC to apply to all medicinal products authorised within the community. In particular, with respect to clinical trials conducted outside the Community on medicinal products destined to be authorised within the Community, it should be verified, at the time of the evaluation of the application for authorisation, that these trials were conducted in accordance with the principles of good clinical practice and the ethical requirements equivalent to the provisions of that Directive. 1
2 Article 6(1) of Regulation No (EC) 726/2004 and Article 8 (ib) of Directive 2001/83/EC as amended the MAA dossier to contain: A statement to the effect that clinical trials carried out outside the European Union meets the ethical requirements of Directive 2001/20/EC. Section 4 of Introduction to Annex I - Directive 2003/63/EC : applicants shall take into account the scientific guidelines relating to the quality, safety and efficacy of medicinal products for human use Dare effettiva attuazione alla Direttiva 2001/83/CE modificata da Direttiva 2003/63/CE (Codice Comunitario sui medicinali)- Recepimento D.L.vo 219/2006 Le sperimentazioni cliniche eseguite fuori dalla Comunità europea concernenti medicinali destinati ad essere utilizzati nella Comunità europea devono essere predisposte, attuate e descritte secondo la buona pratica clinica ed i principi etici pertinenti, sulla base di principi equivalenti alle disposizioni della direttiva 2001/20/CE. Le sperimentazioni devono essere eseguite conformemente ai principi etici contenuti ad esempio nella dichiarazione di Helsinki. 2
3 PROBLEMATICHE ETICHE NELLE SPERIMENTAZIONI NEI PAESI IN VIA DI SVILUPPO (PVS) Sempre più sperimentazioni vengono condotte nei paesi in via di sviluppo. Si stima che il 20-30% dell attività di sperimentazione clinica globale sia svolta in tali Paesi. Le sperimentazioni riguardano spesso patologie dei Paesi sviluppati (es.colesterolo, depressione, ecc) e patologie come malaria e tubercolosi presenti nei PVS. Motivazioni: 1) Bassi costi 2) sperimentazioni più brevi 3) standard etici meno vincolanti e minori controlli AIM of The Trial audited: to detect the efficacy and safety of an IMP versus Placebo in the early treatment of patients who cannot obtain standard care immediately COUNTRIES in Africa and ASIA 6 3
4 MAIN STEPS OF THE TRIAL Some of the inclusion criteria: patients with: a) clinical symptoms/diagnosis of pathology under study b) patients who do not have and cannot obtain standard care immediately 7 1. Involvement of the population of Villages to explain the Clinical Trial ( Community mobilization ), to obtain the Community Consent; 2. Selection and training of Field Workers in villages (F.W.); 3. Investigators visit villages and communities within the area that provide their permission to identify and train F.W.s 4. Medication randomised to IMP or Placebo and provided to FWs 8 4
5 5. FWs trained to identify patients with clinical symptoms and to treat if: a) the patient meets the inclusion/exclusion criteria b) the standard of care is not available c) I.C. has been given in writing; d) patients or guardians say that they agree to go to nearest health facility; e) a biological sample to confirm diagnosis is willingly provided 6. The patient is treated and referred to health facility where patient can receive: a) definite diagnosis b) standard treatment Some of the Main Issues audited: I) Ethical Aspects related to Placebo II) Ethical and operational aspects related to Informed Consent (IC) III) Field Workers (F.W.) selection, training and SOPs IV) SOPs and operational measures related to treatment 10 5
6 I) ETHICAL ASPECTS RELATED TO PLACEBO 1) Proof that C.T. received a favorable opinion : a) by an international or E.U. Ethics Committee (ETH.C) in compliance with GCP b) by independent local Ethics Committees in compliance with GCP requirements 2) Proof that members of ETH.Cs had no conflict of interests 3) Documentation showing that the placebo issue has been suitably discussed by the ETH.Cs and in the protocol 11 4) Documentation showing that the discussion on placebo took into consideration: a) the GCP principle 2.3; the Declaration of Helsinki point 2.1. ; The rights, safety and wellbeing of the trial subjects should prevail over the interest of science and society. b) whether in the local environment there was or was not available an effective treatment/standard of care that could be used instead of placebo; c) whether another design was possible eg was it possible or not possible to compare IMP treatment versus historical data available in the scientific literature. 12 6
7 5) Documentation showing that all concerns of ETH.Cs had been solved and that before the beginning of C.T. sponsor/investigators answered satisfactorily all questions raised by ECs 6) Documentation showing ETH.Cs periodic review of C.T., mainly to possible problems related to placebo 13 II) ETHICAL AND OPERATIONAL ASPECTS RELATED TO INFORMED CONSENT 1. Documentation and interviews with investigators and FWs showing that I.C. were obtained, respecting local traditional customs: i.e. involvement and information provided to: a) chiefs of villages and traditional healers of villages; b) other villages leaders and religious leaders; c) the whole community or village (Community Consent Seminars); d) patients or patients' guardians; 14 7
8 III) Field Workers (F.W.) requirements, training, selection and SOPs 2. Documentation of how people understood the principle of the placebo? 3. Why they accepted the possibility of placebo? 4. Whether it was possible to check the finger prints on informed consent document? 15 1) Documentation showing and/or interview confirming: a) Presence of minimum requirements foreseen for F.W. and for F.W. Supervisors (F.W.S.) b) Contents and methodology and material of training courses: list of trainers and trainees c) F.W. and F.W.S. content of learning/selection 16 8
9 d) Provision of material for F.W. as: Training course brochure SOPs F.W. Diary/note books CRF F.W.S. Registers for traceability of main steps of C.T. Material for finger prints for IC Material for taking biological samples Thermometer etc. IMP in packaging that would prevent contamination in remote villages Bicycle, etc 17 IV) SOPs and operational measures related to treatment and related source documents : e.g. 1) Clear SOPs/written instructions for treatment: a) I.C., patients recruitment; treatment; traceability of treatment; etc b) use of treatment code labels and identifiers (stickers) for each treatment that were stuck on: CRFs; biological samples tube; I.C. forms 18 9
10 c) for consequent problems related to: - cases of more than one treatment for the same patient (e.g. 2 stickers on CRF) 2) SOPs for management of FW s notebook/diaries - cases of more than one sticker on biological sample tube taken 3) Source Documents: A) F.W. Diaries/notebooks - consistent items in the CRF - consistent training for FW
11 B) F.W.Registers with information about traceability of CT crucial steps, i.e. a) date and time of symptoms; b) date and time of other treatments before randomization; c) date and time of treatment; d) if the IMP was damaged and its code N ; e) in case of d): if another IMP was used and its code N ; f) date and time of: biological sample taken biological sample given to laboratory whether patient referred to health facilities - whether patient arrived at facility standard of care given in the health facilities diagnosis in health facilities results of biological sample analysis etc 21 11
12 4) Registers: - List of FW Supervisors and of their FWs - Register with periods of work of FW and FWS - List of villages/community within the responsibility of each FW 5) Interviews confirming: F.W. approach to obtain I.C. F.W. methodology for IMP treatment F.W. methodology to convince patients (or guardian) to proceed to health facilities for standard of care diagnosis and management etc. etc
13 GRAZIE PER L ATTENZIONE 13
Commission Guidelines for the implementation of the Clinical Trials Regulation NTA Ethics Oslo
Commission Guidelines for the implementation of the Clinical Trials Regulation NTA Ethics 30.1.2017 Oslo 3.2.2017 O. Konttinen 1 Background Based on directive 2001/20/EC of the clinical trials on medicinal
More informationJoint Statement on the Application of Good Clinical Practice to Training for Researchers
Joint Statement on the Application of Good Clinical Practice to Training for Researchers HRA, MHRA, Devolved Administrations for Northern Ireland, Scotland and Wales v1.1 12/10/17 Summary This joint statement
More informationJoint R&D Support Office SOP S-2011 UHL
UNIVERSITY OF LEICESTER & UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST JOINT RESEARCH & DEVELOPMENT SUPPORT OFFICE STANDARD OPERATING PROCEDURES Joint R&D Support Office SOP S-2011 UHL Site Initiation for
More informationResearch Governance Framework 2 nd Edition, Medicine for Human Use (Clinical Trial) Regulations 2004
Title: Outcome Statement: Research Auditing and Monitoring Procedures Researchers in the Trust and research partners will be informed about the requirements and procedures involved in research audit and
More informationTRAINING NEEDS FOR CPP MEMBERS IN FRANCE
TRAINING NEEDS FOR CPP MEMBERS IN FRANCE Professeur Sylvie Hansel-Esteller EFGCP Bruxelles 30-31/01/2007 Les comités de protection des personnes Long experience since 1988 date of implementation of the
More informationPharmacists' involvement in clinical trials and ethical committees
19th Congress of the European Associat Barcelona, Spain, 26-28 March 2014 Barcelona, Spain, 26-28 19 th CONGRESS OF THE EUROPEAN ASSOCIATION OF HOSPITAL PHARMACISTS Pharmacists' involvement in clinical
More informationOverview of the IMB s. Good Clinical Practice. Deirdre O Regan GCP/Pharmacovigilance. GCP Seminar Dublin, 27 th January 2010.
Overview of the IMB s Approach to Inspection of Good Clinical Practice GCP Seminar Dublin, 27 th January 2010 Deirdre O Regan GCP/Pharmacovigilance Inspection Manager Slide 1 Introductions/Organisation
More informationISO14155: 2011 Clinical investigation of medical devices for human subjects - Good Clinical Practice - ISO TC194 WG4 Madoka Murakami PMDA, Japan
ISO14155: 2011 Clinical investigation of medical devices for human subjects - Good Clinical Practice - ISO TC194 WG4 Madoka Murakami PMDA, Japan What is GCP? Good Clinical Practice (GCP) is an international
More informationPHARMACY, MEDICINES & POISONS BOARD GUIDELINES FOR REVIEW/EVALUATION CLINICAL TRIAL APPLICATIONS FOR VACCINES AND BIOLOGICALS MALAWI
PHARMACY, MEDICINES & POISONS BOARD GUIDELINES FOR REVIEW/EVALUATION OF CLINICAL TRIAL APPLICATIONS FOR VACCINES AND BIOLOGICALS IN MALAWI 1. INTRODUCTION The clinical trial application must undergo a
More informationFirst inspection of a Legal Representative in the EU by local authority
First inspection of a Legal Representative in the EU by local authority Michael Gierend, DVM PhD on behalf of Edgar Fenzl, MD, PhD FGK Representative Service GmbH ( www.fgk-rs.com ) Munich, Germany CEMO
More informationETHICS COMMITTEE: ROLE, RESPONSIBILITIES AND FUNCTIONS K.R.CHANDRAMOHANAN NAIR DEPARTMENT OF ANATOMY, MEDICAL COLLEGE, THIRUVANANTHAPURAM
ETHICS COMMITTEE: ROLE, RESPONSIBILITIES AND FUNCTIONS K.R.CHANDRAMOHANAN NAIR DEPARTMENT OF ANATOMY, MEDICAL COLLEGE, THIRUVANANTHAPURAM Outline Introduction Composition Responsibilities of IEC Responsibilities
More informationTraining components for GCP. inspectors in PMDA. Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA
Training components for GCP inspectors in PMDA Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA Content 1. Conformity inspection in the training program for newcomers to PMDA 2. The training
More informationCLIC Clinical Investigator (And Site Staff) Certification
CLIC Clinical Investigator (And Site Staff) Certification CLIC Level 1: 23-24 March 2015 CLIC Level 2: 25-27 March 2015 Cape Town (Venue to be confirmed) C PD points L e v e l 1 : 1 4 G e n e r a l, 2
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Routine Project Audit SOP Number: 6 Version Number: 2.0 Supercedes: 1.0 Effective date: August 2013 Review date: August
More informationTrial Management: Trial Master Files and Investigator Site Files
Title: Outcome Statement: Written By: Trial Management: Trial Master Files and Investigator Site Files Staff working on research studies in NSFT will be informed about the requirements of setting up and
More information2 Stage procedure: Special attention to the 1st stage. How to build a successful proposal
2 Stage procedure: Special attention to the 1st stage How to build a successful proposal 1 Why two stage procedure? History: two stage calls introduced in 3 rd Call FP7 Health 2009, since then increasing
More informationDocument Title: Study Data SOP (CRFs and Source Data)
Document Title: Study Data SOP (CRFs and Source Data) Document Number: SOP047 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
More informationStandard Operating Procedure. Essential Documents: Setting Up a Trial Master File. SOP effective: 19 February 2016 Review date: 19 February 2018
Standard Operating Procedure SOP number: SOP full title: SOP-JRO-06-003 Essential Documents: Setting Up a Trial Master File SOP effective: 19 February 2016 Review date: 19 February 2018 SOP author signature:
More informationDocument Title: Investigator Site File. Document Number: 019
Document Title: Investigator Site File Document Number: 019 Version: 1.1 Ratified by: R&D Committee Date ratified: 03/10/2017 Name of originator/author: Directorate: Department: Name of responsible individual:
More informationCourse program. Good Clinical Practice (GCP) course for surgeons
Course program Good Clinical Practice (GCP) course for surgeons 2 Good Clinical Practice (GCP) course for surgeons 7 Principles of Education Based on needs Relevant Interactive Leads to verifiable outcomes
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Site Selection and Initiation SOP number: TM 005 SOP category: Trial Management Version number: 03 Version date: 19 December
More informationSite Closedown Checklist for UoL Sponsored CTIMP Studies
Site Closedown Checklist for UoL Sponsored CTIMP Studies Site Information Site: Study Title: UoL study number: Centre name: Investigator: Date of Visit: Date of Report Date Responses due by: List of site
More informationMHRA Findings Dissemination Joint Office Launch Jan Presented by: Carolyn Maloney UHL R&D Manager
MHRA Findings Dissemination Joint Office Launch Jan. 2012 Presented by: Carolyn Maloney UHL R&D Manager Purpose of presentation To feed back abridged findings from March 2011 MHRA Statutory Systems Inspection
More informationMARIE CURIE ACTIONS INDIVIDUAL FELLOWSHIPS How to submit your proposal with UNIFI
MARIE CURIE ACTIONS INDIVIDUAL FELLOWSHIPS How to submit your proposal with UNIFI 1 AREA SERVIZI ALLA RICERCA E TRASFERIMENTO TECNOLOGICO MARIE CURIE ACTIONS INDIVIDUAL FELLOWSHIPS How to submit your
More informationSOP16: Standard Operating Procedure for Establishing Sites and Centres - Site Setup
SOP16: Standard Operating Procedure for Establishing Sites and Centres - Site Setup Authorship Team: Leanne Quinn for Joint SOP Group on Trial Processes (viz Ian Russell, Anne Seagrove, Jemma Hughes, Yvette
More informationStandard Operating Procedures (SOP) Research and Development Office
Standard Operating Procedures (SOP) Research and Development Office Title of SOP: Principles of Data Collection and Storage SOP Number: 8 Supercedes: 1.0 Effective date: August 2013 Review date: August
More informationSTANDARD OPERATING PROCEDURE SOP 325
STANDARD OPERATING PROCEDURE SOP 325 STUDY START UP ACTIVITIES FOR CLINICAL RESEARCH TRIALS Version 1.4 Version date 28.03.2017 Effective date 28.03.2017 Number of pages 7 Review date April 2019 Author
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Site Selection and Initiation SOP number: TM-005 SOP category: Trial Management Version number: 04 Version date: 10 July
More informationMINISTERO DELL'ISTRUZIONE DELL'UNIVERSITÀ E DELLA RICERCA
MINISTERO DELL'ISTRUZIONE DELL'UNIVERSITÀ E DELLA RICERCA Dipartimento per la formazione superiore e per la ricerca Direzione Generale per il coordinamento, la promozione e la valorizzazione della Ricerca
More informationSOP WP6-QUAL-04, Version 1.0, 23 February 2014 Page 1 of 8. SOP Title: Laboratory (GCLP) supervision visits
SOP WP6-QUAL-04, Version 1.0, 23 February 2014 Page 1 of 8 SOP Title: Laboratory (GCLP) supervision visits Project/study: NIDIAG: this SOP applies to all NIDIAG clinical studies (WP2). 1. Scope and application
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Recording and Reporting Deviations, Violations, Potential Serious Breaches, Serious Breaches and Urgent Safety Measures
More informationStandard Operating Procedure (SOP) for Reporting Serious Breaches in Clinical Research
Standard Operating Procedure (SOP) for Reporting Serious Breaches in Clinical Research For Completion by SOP Author Reference Number PHT/RDSOP/002 Version V2.0 07 Apr 2016 Document Author(s) Document Reviewer(s)
More informationHarrison Clinical Research. Monitoring of Clinical Trials - Quality Management from a CRO s Perspective
Harrison Clinical Research Monitoring of Clinical Trials - Quality Management from a CRO s Perspective www.harrisonclinical.com 1 17Sep2009 Overview: Monitoring of Clinical Trials 1. Discovering and developing
More informationEuropean Medicines Agency Inspections ANNEX V TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: PHASE I UNITS
European Medicines Agency Inspections London, 23 July 2008 EMEA/INS/GCP/197215/2005 Procedure no.: INS/GCP/3/V ANNEX V TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: PHASE I UNITS GCP
More informationHORIZON Il nuovo quadro europeo di ricerca e Innovazione. Foggia, gennaio 2014
HORIZON 2020 Il nuovo quadro europeo di ricerca e Innovazione Foggia, 30-31 gennaio 2014 Antonio Carbone Punto Contatto Nazionale PMI ICT Finanza di rischio carbone@apre.it VERSO HORIZON 2020 7 PQ CIP
More informationNew European Union Clinical Trial Regulations
New European Union Clinical Trial Regulations Incorporate Monitoring and Safety Reporting Techniques into U.S. and EU Clinical Trial SOPs Anita K. Murthy Deputy Director, Global Regulatory Affairs Bayer
More informationSTANDARD OPERATING PROCEDURE SOP 710. Good Clinical Practice AUDIT AND INSPECTION. NNUH UEA Joint Research Office. Acting Research Services Manager
STANDARD OPERATING PROCEDURE SOP 710 Good Clinical Practice AUDIT AND INSPECTION Version 1.3 Version date 27.02.2018 Effective date 3.03.2018 Number of pages 10 Review date February 2020 Author Role Approved
More informationSponsor Responsibilities. Roles and Responsibilities. EU Directives. UK Law
EU Directives Pharmacovigilance Legislation, SOPs and Reporting Louise Boldy, Governance & Safety Manager David Martin, Pharmacovigilance Monitor EU Legislation 2001/20/EC 2005/28/EC EudraLex Vol 10 UK
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Delegated Responsibilities in Research Projects SOP Number: 11 Version Number: 2.0 Supercedes: 1.0 Effective date: August
More informationDocument Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026
Document Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026 Version: 1.1 Ratified by: Committee Date ratified: 03/10/2017 Name of originator/author: Directorate: Department:
More informationStandard Operating Procedures
Standard Operating Procedures 6.5.1 Study Recruitment 2008 History Versi Date Author Reason on 1.1 18 th July 2007 B Fazekas New procedure 1.2 21 st January B Fazekas Update after MAB review 2008 1.3 19
More informationDocument Number: 006. Version: 1. Date ratified: Name of originator/author: Heidi Saunders, Senior Portfolio Coordinator
including Roles and Responsibilities for the Conduct of Research Studies and Clinical Trials including CTIMPs (Clinical Trials of Investigational Medicinal Products) Document Number: 006 Version: 1 Ratified
More informationThe implementation of the Clinical Trial Regulation (CTR, n 536/2014) in Belgium. and impact on the ethical review process
1 The implementation of the Clinical Trial Regulation (CTR, n 536/2014) in Belgium and impact on the ethical review process 2 1. Clinical Trials on Medicinal Products for Human Use: Change of the Legal
More informationStudy Monitoring Plan Template
Study Monitoring Plan Template Sponsor Reference Number: Study Title: Principal Investigator: Study Centre: The Sponsor risk assessment form and the trial risk based monitoring strategy appendices 2 &
More informationVersion Number: 004 Controlled Document Sponsor: Controlled Document Lead:
Chief Investigators and Principal Investigators in Research Policy CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Policy Governance To set out the responsibilities of
More informationGovernance %%.4- r2&% Queen s University Belfast. Standard Operating Procedure Research Governance. r2.aoc7. Research and Enterprise
Queen s University Belfast Research and Enterprise Standard Operating Procedure Research Governance Title: Delegation of Responsibilities SOP Reference QUB-ADRE-005 Date prepared 23 June 2008 Number: Version
More informationStandard Operating Procedure INVESTIGATOR OVERSIGHT OF RESEARCH. Chief and Principal Investigators of research sponsored and/or hosted by UHBristol
Standard Operating Procedure INVESTIGATOR OVERSIGHT OF RESEARCH SETTING FOR STAFF ISSUE Trustwide Chief and Principal Investigators of research sponsored and/or hosted by UHBristol Oversight of research
More informationSurvey of Research Nurse Training and Experience in a Paediatric Clinical Trial Setting
Survey of Research Nurse Training and Experience in a Paediatric Clinical Trial Setting The following survey has been generated by the European Network of Paediatric Research at the European Medicines
More informationVersion Number: 003. On: September 2017 Review Date: September 2020 Distribution: Essential Reading for: Information for: Page 1 of 13
CONTROLLED DOCUMENT Reporting Research Incidents and Breaches Policy CATEGORY: CLASSIFICATION: PURPOSE Controlled Number: Document Policy Governance To set out the framework and principles for reporting
More informationTraining, Site Selection and Human Subject Protection: Factors to Consider When Developing a Monitoring Plan
Training, Site Selection and Human Subject Protection: Factors to Consider When Developing a Monitoring Plan Cynthia F. Kleppinger, M.D. Senior Medical Officer Office of Scientific Investigations Office
More informationSTANDARD OPERATING PROCEDURE SOP 715. Principles of Clinical Research Laboratory Practice
STANDARD OPERATING PROCEDURE SOP 715 Principles of Clinical Research Laboratory Practice Version 1.2 Version date 13.11.2015 Effective date 24.04.2017 Number of pages 9 Review date June 2018 Author Role
More informationDocument Title: Informed Consent for Research Studies
Document Title: Informed Consent for Research Studies Document Number: SOP003 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
More informationThis Agreement dated DD/MM/YYYY (the Effective Date ) is between
Clinical Trial Delegation of Sponsorship Responsibilities to Chief This Agreement dated DD/MM/YYYY (the Effective Date ) is between Nottingham University Hospitals NHS Trust, Derby Road, Nottingham, NG7
More informationUnofficial copy not valid
Page 2 (9) CONTENTS 1. PURPOSE... 3 2. DEFINITIONS... 3 3. RESPONSIBILITY... 3 4. INVESTIGATOR SELECTION... 3 4.1 Identification of Investigator s... 3 4.2 Initial Contacts... 4 4.3 Distribution of Pre-Study
More informationAPEC Preliminary Workshop: Review of Drug Development in Clinical Trials
APEC Preliminary Workshop: Review of Drug Development in Clinical Trials Session 9 B Clinical Trial Assessment Patient Protection Informed Consent Susan D Amico Vice President and Global Head Clinical
More informationQuality Assurance in Clinical Research at RM/ICR. GCP Compliance Team, Clinical R&D
Quality Assurance in Clinical Research at RM/ICR GCP Compliance Team, Clinical R&D Slide 1 of 13 What is Quality Assurance? The maintenance of a desired level of quality in a service or product, especially
More informationRisk Assessment and Monitoring
Version 1.3 Effective date: 25 May 2012 Author: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Version 1.3 25 May 2012 Version 1.2 29 January 2010
More informationMedical devices briefing for patients: Patient safety in the new Regulation
Medical devices briefing for patients: Patient safety in the new Regulation 20/12/2016 Patient safety is an important priority for the European Patients Forum, and it was also our main priority in our
More informationCLINICAL RESEARCH POLICY
CLINICAL RESEARCH POLICY Approved by: Date of approval: Originator: Medical Director POLICY STATEMENT Good quality clinical research is important for furthering our understanding of the problems encountered
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Sponsorship SOP-RES-001 Version Number 3 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov 2018 Author(s) Reviewer(s) Teresa
More informationGood Clinical Practice: A Ground Level View
Good Clinical Practice: A Ground Level View Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Clinical Research Administration Research Institute,
More informationStorage and Archiving of Research Documents SOP 6
Storage and Archiving of Research Documents SOP 6 SOP Title Storage and Archiving or Research Documents (Formerly Storage and Archiving Requirements ) SOP No. SOP 6 Author Consulted Departments Lead Manager
More informationInformed Consent SOP Number: 25 Version Number: 6.0 Effective Date: 1 st September 2017 Review Date: 1 st September 2019
Standard Operating Procedures (SOP) for: Informed Consent SOP Number: 25 Version Number: 6.0 Effective Date: 1 st September 2017 Review Date: 1 st September 2019 Author: Reviewer: Reviewer: Authorisation:
More informationChanges in the Medical Device Legislation; the day after. Jan Bart Hak 1
PPN Najaarsbijeenkomst 21 November 2017 Changes in the Medical Device Legislation; the day after. How much time do we have left? Jan Bart Hak Jan Bart Hak 1 Company Leading consultancy and project management
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Adverse Event Identification, Recording and Reporting in Clinical Trials of Investigational Medicinal SOP-RES-019 Version Number 2 Issue Date 08 th Dec
More informationSOP-QA-28 V2. Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys, Head of School
Title: Effective Date: 1-4-17 Review Date: 1-4-20 Author: Richard Cowie, QA Manager QA Approval: Richard Cowie, QA Manager Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys, Head
More information1. Introduction, purpose of this Standard Operating Procedure (SOP)
SOP-CTN-001- Clinical Trial Network - General Organisation and Principles European Society of Anaesthesiology Details Document Type Document name Ref # Version Effective from Review date Owner Prepared
More informationEuropean CRO Federation
European CRO Federation The interface between Industry CRO and Clinical Trials Networks: Defining the Roles EMA, London, 22 March 2012 Dr. Martine Dehlinger-Kremer Vice President Global Regulatory Affairs,
More informationMonitoring Clinical Trials
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationKeele Clinical Trials Unit
Keele Clinical Trials Unit Standard Operating Procedure (SOP) Summary Box Title Safety Reporting and Pharmacovigilance SOP Index Number SOP 20 Version 4.0 Approval Date 31-Jan-2017 Effective Date 14-Feb-2017
More informationGuidance for the conduct of good clinical practice inspections
23 August 2017 EMA/839541/2015 Guidance for the conduct of good clinical practice inspections Adopted by GCP Inspectors Working Group (GCP IWG) 4 September 2017 Keywords Conduct of GCP inspections 30 Churchill
More informationGCP INSPECTION CHECKLIST
(This list is not all inclusive; item may be added &/or deleted as per the Study/Site/Sponsor/Lab) I. General. Name and address of the clinical trial site Tel. No. & e- mail:. Date of Inspection. Inspection
More informationGood Clinical Practice. Lisa de Blieck MPA CCRC Clinical Trials Coordination Center
Good Clinical Practice Lisa de Blieck MPA CCRC Clinical Trials Coordination Center Good Clinical Practice (GCP) An international standard for the design, conduct, performance, monitoring, auditing, recording,
More informationSTH Researcher. Recording of research information in patient case notes
STANDARD OPERATING PROCEDURE STH Researcher Recording of research information in patient case notes SOP History None SOP Number A108 Created Research Department (AL) SUPERSEDED Final 1.3 Version 3.5 Date
More informationDocument Title: Document Number:
including Document Title: Document Number: Version: 2.0 Ratified by: Committee Date ratified: 25/01/2018 Name of originator/author: Directorate: Department: Name of responsible individual: Rachel Fay Corporate
More informationJUNCO Journal of UNiversities and international development COoperation n. 1/2017
POSITIVE AND NEGATIVE EFFECTS OF FINANCIAL AND NON-FINANCIAL INCENTIVES MECHANISM FOR HEALTH WORKERS IN RURAL AND REMOTE AREAS OF ETHIOPIA. FOCUS ON OROMIA, SOMALI AND TIGRAY REGIONS Maria Alessandra Brocardo
More informationGuidance for applicants requesting scientific advice
7 December 2017 EMEA/CVMP/SAWP/172329/2004 Rev. 5 Veterinary Medicines Division Introduction The Scientific Advice Working Party (SAWP-V) of the Committee for Medicinal Products for Veterinary Use (CVMP)
More informationERASMUS+ PROGRAMME 2017/2018 ACADEMIC YEAR
ERASMUS+ PROGRAMME 2017/2018 ACADEMIC YEAR First cycle degree programme in Language Mediation and Intercultural Communication Second cycle degree programme (laurea magistrale) in Languages and Culture
More informationScientific Advice and Protocol Assistance at the EMEA
Univ.-Doz. Dr. Bernhard Fischer, MBA P.O. Box 4, A-1097 Vienna, Austria Phone: +43-(0)664-1432919 Fax: +43-(0)664-1477280 Mail: biotechconsulting@aon.at URL: www.biotechnologyconsulting.eu Regulatory Affairs
More informationA multi-ethnic multi-national approach to ethical approval of clinical trials involving Thalassaemia patients: the DEEP lesson. Prof.
13 th International Conference on Thalassaemia Abu Dhabi, 20-23 October 2013 A multi-ethnic multi-national approach to ethical approval of clinical trials involving Thalassaemia patients: the DEEP lesson
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number End of Study Report SOP-RES-027 Version Number 2 Issue Date 15 Apr 2016 Effective Date 26 May 2016 Review Date 26 May 2018 Author(s) Reviewer(s) Natalie
More informationEuropean network of paediatric research (EnprEMA)
17 February 2012 EMA/77450/2012 Human Medicines Development and Evaluation Recognition criteria for self assessment The European Medicines Agency is tasked with developing a European paediatric network
More informationSPECIFIC PRIVACY STATEMENT IMI JU
SPECIFIC PRIVACY STATEMENT IMI JU Innovative Medicines Initiative Joint Undertaking - Proposals Evaluation and Grants Management This statement concerns the processing operation called "Innovative Medicines
More informationR. Fay, Research Governance & GCP Manager K. Mahiouz, Clinical Trials Facilitator E. Clough, R&D Governance Operations Manager
Standard Operating Procedures (SOP) for: BH/QMUL Sponsorship of CTIMPs, ATMPs and Clinical Trials of non- CE marked Medicinal Devices Process for Researchers SOP Number: 11a Version Number: V1.0 Effective
More informationThe New EU PV Legislation: View from the European Commission
The New EU PV Legislation: View from the European Commission International seminar 26 May 2011 Lenita LINDSTRÖM Senior Policy Officer Pharmaceuticals Unit/DG SANCO Rationale for the revision Calls for
More informationRoles & Responsibilities of Investigator & IRB
Roles & Responsibilities of Investigator & IRB Jaranit Kaewkungwal Mahidol University Regulatory & Guidelines Regulatory & Guidelines GCP & Computer / Database Management Systems International Conference
More informationTrial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs
R&D Department Trial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs Hull And East Yorkshire Hospitals NHS Trust 2010 All Rights Reserved No part of this document may be reproduced, stored
More informationA Screen patients G Review/Accountability/Sign off Form 2:Dosing Log M IMP Supply/Management. SAE clinical review/causality Assessment and Sign off
Site Delegation Log Study Name: Hospital: ELFIN EudraCT No: 2012-004260-22 REC Reference: 13/EM/0118 Title: Investigator: A multi-centre randomised placebo-controlled trial of prophylactic enteral lactoferrin
More informationMarie-Claire Rickard, RG and GCP Manager Jimena Lovos, Quality Assurance Manager Elizabeth Clough, R&D Governance Operations Manager
Standard Operating Procedures (SOP) for: Pharmacovigilance processing for the JRMO SOP Number: 26c Version Number: V1 Effective Date: 5/8/16 Review Date: 5/8/17 Author: Reviewer: Reviewer: Authorisation:
More informationGeneral Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility
General Administration GA 102.01 STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility Approval: Nancy Paris, MS, FACHE President and CEO (17 July 2014) (Signature and
More informationQuestions and answers on the procedure of PIP compliance verification at EMA, and on paediatric rewards
15 December 2014 EMA/PDCO/179892/2011 Rev. 2 Product Development Scientific Support Paediatric Medicines Questions and answers on the procedure of PIP compliance verification at EMA, and on paediatric
More informationThe international network of H2020 Energy National Contact Points (NCPs)
The international network of H2020 Energy National Contact Points (NCPs) Enrico Mazzon APRE Agency for the Promotion of European Research Coordinator of the C-Energy 2020 network Italian National Contact
More informationDocument Title: Research Database Application (ReDA) Document Number: 043
Document Title: Research Database Application (ReDA) Document Number: 043 Version: 1 Ratified by: Committee Date ratified: 30 September 2014 Name of originator/author: Directorate: Department: Name of
More informationSubmission of a clinical trial for access to ECRIN services Notice to the Applicant
Submission of a clinical trial for access to ECRIN services Notice to the Applicant BEFORE SUBMITTING YOUR PROTOCOL Please, contact the European Correspondent (EuCo) in your country. The list of EuCos
More informationInvestigator-Initiated Studies: When you re the Sponsor. Cheri Robert & Tammy Mah-Fraser
Investigator-Initiated Studies: When you re the Sponsor Cheri Robert & Tammy Mah-Fraser ACRC Clinical Research Conference Edmonton, AB October 15, 2014 Session Objectives Define roles of the investigator,
More informationhttps://helsedirektoratet.no/english Regulatory and ethics bodies involved in approval process
Medical Devices - NORWAY Competent authority Contact Details Contact Name 1 Norwegian Directorate of Health Email Department medisinsk.utstyr@ helsedir.no Address PO Box 7000; St. Olavs plass ZIP/City
More informationApplying to EFSA calls
Applying to EFSA calls Stef Bronzwaer Advisory Forum and Scientific Cooperation Unit Istituto Superiore di Sanita, Roma, 12 March 2012 Grants and procurement The project cycle Planning phase: Identifying
More informationPERFORMANCE IN INITIATING AND DELIVERING CLINICAL RESEARCH INFORMATION SUBMISSION GUIDELINES
PERFORMANCE IN INITIATING AND DELIVERING CLINICAL RESEARCH INFORMATION SUBMISSION GUIDELINES Version Control Item 20 Items 22, 23 Item 27 Added item regarding responsibility of providers to submit successfully
More informationStudy Start-Up SS STANDARD OPERATING PROCEDURE FOR PRE-STUDY SITE VISIT (PSSV)
Replaces previous version 203.01: 01 July 2014 Study Start-Up SS 203.01 STANDARD OPERATING PROCEDURE FOR PRE-STUDY SITE VISIT (PSSV) Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature
More informationOFFICE FOR RESEACH PROCEDURE. Documentation of Investigational Site Qualifications, Adequacy of Resources and Training Records
OFFICE FOR RESEACH PROCEDURE Documentation of Investigational Site Qualifications, Adequacy of Resources and Training Records 1. Purpose: To describe the procedures related to the appropriate documentation
More information